[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”grid” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern” css=”.vc_custom_1463146184322{padding-bottom: 70px !important;}”][vc_column offset=”vc_col-lg-offset-1 vc_col-lg-10 vc_col-md-offset-1 vc_col-md-10″][vc_single_image image=”1282″ img_size=”full” alignment=”center” qode_css_animation=””][vc_empty_space][vc_column_text]LAS VEGAS, November 1, 2017/PR Newswire/–GB Sciences, Inc. (OTCQB: GBLX) inducts a Scientific Advisory Board to provide oversight for product development within GB Sciences’ intellectual property portfolio, consisting of three original patent applications, one licensed patent application, and one licensed approved patent. GB Sciences remains committed to discovering novel cannabis-based therapies for disease-specific applications; as well as producing standardized patent-pending formulations and ensuring their efficacy through well-controlled clinical trials. The Scientific Advisory Board will be tasked with efficiently managing GB Sciences’ resources while creating and testing their proprietary cannabis-based formulas.
The Scientific Advisory Board will be chaired by Dr. Andrea Small Howard, Chief Science Officer of GB Sciences, Inc. “We are very honored to welcome some new members to our Scientific Advisory Board this year; as well as, Dr. Helen Turner, who has worked with GB Sciences for the past four years. Dr. Turner, VP of Innovation, Dean of Natural Sciences and Mathematics at Chaminade University, has been my collaborator on the discovery of our novel cannabis-based therapies since the beginning, and she is a co-inventor with me on all of GB Sciences’ original patent applications,” said Dr. Small-Howard. “Joining the team this year are Dr. Norbert Kaminski of Michigan State University, whose laboratory was the first to discover cannabinoid receptor expression in the immune system, who pioneered studies of the effects of cannabis on immune modulation, and who has more recently been studying the effects of cannabis use on patients with HIV/AIDS. Dr. Carlos F. Ríos-Bedoya from McLaren Health, has been a pioneer in the use of mobile technology and Patient Reported Outcome software to expedite data gathering in clinical trials. In addition, Dr. Ríos-Bedoya brings experience in clinical trial protocol development and statistics to our team.” Full biographies for our Scientific Advisory Board members are available on our website.
“GB Sciences is committed to putting safe and effective cannabis-based medicines into the hands of the patients who need it, and doing it as quickly as possible,” said John Poss, CEO and Chairman of GB Sciences, Inc. “We believe that our Scientific Advisory Board has the skills and connections to make this happen.”[/vc_column_text][/vc_column][/vc_row][vc_row row_type=”parallax” parallax_content_width=”in_grid” text_align=”center” background_image=”219″ full_screen_section_height=”no”][vc_column][vc_separator type=”transparent” thickness=”0″ up=”0″ down=”177″][icons icon_pack=”font_elegant” fe_icon=”icon_quotations” size=”fa-lg” type=”square” custom_size=”45″ custom_shape_size=”40″ border_radius=”100″ border=”yes” target=”_self” icon_color=”#000000″ icon_hover_color=”#141212″ background_color=”rgba(255,255,255,0.01)” hover_background_color=”#ffffff” border_color=”#ffffff” border_width=”1″][vc_separator type=”transparent” thickness=”0″ up=”0″ down=”35″][vc_column_text]
GB Sciences is committed to putting safe and effective cannabis-based medicines into the hands of the patients who need it, and doing it as quickly as possible.
[/vc_column_text][vc_separator type=”transparent” thickness=”0″ up=”0″ down=”26″][vc_column_text]
– John Poss, CEO GBSciences
[/vc_column_text][vc_separator type=”transparent” thickness=”0″ up=”0″ down=”174″][/vc_column][/vc_row]